ALNOV Stock Overview
Provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Novacyt S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.61 |
| 52 Week High | €1.59 |
| 52 Week Low | €0.49 |
| Beta | -1.84 |
| 1 Month Change | 6.04% |
| 3 Month Change | -27.34% |
| 1 Year Change | -13.52% |
| 3 Year Change | -85.79% |
| 5 Year Change | 315.43% |
| Change since IPO | -92.94% |
Recent News & Updates
Recent updates
Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%
Sep 30
Novacyt S.A. (EPA:ALNOV) Stock Catapults 39% Though Its Price And Business Still Lag The Industry
Aug 16Here's Why Novacyt (EPA:ALNOV) Must Use Its Cash Wisely
Aug 15Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price
Jun 14Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?
Nov 28We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate
Jul 04Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)
Jan 24With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Mar 18With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting
Nov 25Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding
Sep 29Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth
Mar 08Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?
Jan 22
Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)
Dec 15We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability
Nov 19Shareholder Returns
| ALNOV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -10.5% | -0.9% | -1.8% |
| 1Y | -13.5% | -28.0% | -4.9% |
Return vs Industry: ALNOV exceeded the French Biotechs industry which returned -28% over the past year.
Return vs Market: ALNOV underperformed the French Market which returned -4.9% over the past year.
Price Volatility
| ALNOV volatility | |
|---|---|
| ALNOV Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALNOV's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALNOV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 240 | Lyn Rees | www.novacyt.com |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.
Novacyt S.A. Fundamentals Summary
| ALNOV fundamental statistics | |
|---|---|
| Market cap | €43.31m |
| Earnings (TTM) | -€45.08m |
| Revenue (TTM) | €22.40m |
1.9x
P/S Ratio-1.0x
P/E RatioIs ALNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNOV income statement (TTM) | |
|---|---|
| Revenue | UK£18.56m |
| Cost of Revenue | UK£29.52m |
| Gross Profit | -UK£10.96m |
| Other Expenses | UK£26.40m |
| Earnings | -UK£37.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | -59.05% |
| Net Profit Margin | -201.27% |
| Debt/Equity Ratio | 0% |
How did ALNOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novacyt S.A. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mathieu Jasmin | Arkeon Finance |
| Johann Carrier | Invest Securities |
| Stefan Hamill | Numis Securities Ltd. |